Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Preprint |
| Published: |
2022
|
| Subjects: | |
| Online Access: | https://arxiv.org/abs/2212.00659 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866911890394841088 |
|---|---|
| author | Boulet, Sandrine Ursino, Moreno Michelet, Robin Aulin, Linda B. S. Kloft, Charlotte Comets, Emmanuelle Zohar, Sarah |
| author_facet | Boulet, Sandrine Ursino, Moreno Michelet, Robin Aulin, Linda B. S. Kloft, Charlotte Comets, Emmanuelle Zohar, Sarah |
| contents | In preclinical investigations, e.g. in in vitro, in vivo and in silico studies, the pharmacokinetic, pharmacodynamic and toxicological characteristics of a drug are evaluated before advancing to first-in-man trial. Usually, each study is analyzed independently and the human dose range does not leverage the knowledge gained from all studies. Taking into account the preclinical data through inferential procedures can be particularly interesting to obtain a more precise and reliable starting dose and dose range. We propose a Bayesian framework for multi-source data integration from preclinical studies results extrapolated to human, which allow to predict the quantities of interest (e.g. the minimum effective dose, the maximum tolerated dose, etc.) in humans. We build an approach, divided in four main steps, based on a sequential parameter estimation for each study, extrapolation to human, commensurability checking between posterior distributions and final information merging to increase the precision of estimation. The new framework is evaluated via an extensive simulation study, based on a real-life example in oncology inspired from the preclinical development of galunisertib. Our approach allows to better use all the information compared to a standard framework, reducing uncertainty in the predictions and potentially leading to a more efficient dose selection. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2212_00659 |
| institution | arXiv |
| publishDate | 2022 |
| record_format | arxiv |
| spellingShingle | Bayesian Framework for Multi-Source Data Integration -- Application to Human Extrapolation From Preclinical Studies Boulet, Sandrine Ursino, Moreno Michelet, Robin Aulin, Linda B. S. Kloft, Charlotte Comets, Emmanuelle Zohar, Sarah Methodology In preclinical investigations, e.g. in in vitro, in vivo and in silico studies, the pharmacokinetic, pharmacodynamic and toxicological characteristics of a drug are evaluated before advancing to first-in-man trial. Usually, each study is analyzed independently and the human dose range does not leverage the knowledge gained from all studies. Taking into account the preclinical data through inferential procedures can be particularly interesting to obtain a more precise and reliable starting dose and dose range. We propose a Bayesian framework for multi-source data integration from preclinical studies results extrapolated to human, which allow to predict the quantities of interest (e.g. the minimum effective dose, the maximum tolerated dose, etc.) in humans. We build an approach, divided in four main steps, based on a sequential parameter estimation for each study, extrapolation to human, commensurability checking between posterior distributions and final information merging to increase the precision of estimation. The new framework is evaluated via an extensive simulation study, based on a real-life example in oncology inspired from the preclinical development of galunisertib. Our approach allows to better use all the information compared to a standard framework, reducing uncertainty in the predictions and potentially leading to a more efficient dose selection. |
| title | Bayesian Framework for Multi-Source Data Integration -- Application to Human Extrapolation From Preclinical Studies |
| topic | Methodology |
| url | https://arxiv.org/abs/2212.00659 |